OCKHAM RESEARCH COMPANY ARCHIVE
OCKHAM RESEARCH COMPANY PROFESSIONAL

Most entrepreneurs want to make pots of money and run the show. Conversely, founders who understand that their goal is to amass wealth will not view themselves as failures when they step down from the top job. Founders who want to manage empires will not believe they are successes if they lose control, even if they end up rich. Such founders will often bring in new CEOs themselves and be more likely to work with their boards to develop new, post-succession roles for themselves.Ĭhoosing between money and power allows entrepreneurs to come to grips with what success means to them.

Entrepreneurs who focus on wealth, such as Jim Triandiflou, who founded Ockham Technologies, can make the leap sooner because they won’t mind taking money from investors or depending on executives to manage their ventures. They may also want to wait until late in their careers, after they have developed broader management skills, before setting up shop.

This fundamental tension requires founders to make “rich” versus “king” trade-offs to maximize either their wealth or their control over the company.įounders seeking to remain in control (as John Gabbert of the furniture retailer Room & Board has done) would do well to restrict themselves to businesses where large amounts of capital aren’t required and where they already have the skills and contacts they need.

OCKHAM RESEARCH COMPANY PROFESSIONAL

More often than not, however, those superior returns come from replacing the founder with a professional CEO more experienced with the needs of a growing company. The author’s studies indicate that a founder who gives up more equity to attract cofounders, new hires, and investors builds a more valuable company than one who parts with less equity. But new research from Harvard Business School professor Wasserman shows that those goals are largely incompatible. Quassia Biopharma China Private Quassia Biopharma is a biotech company.Why do people start businesses? For the money and the chance to control their own companies, certainly. EnCare Biotech aims to develop a new therapeutic antibody for the prevention of heart failure after acute myocardial infarction (heart attack). Their lead product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. Pharchoice Therapeutics China n/a Pharchoice Therapeutics is a Chinese biotech company.ĮnCare Biotech Netherlands Private Encare Biotech is a spin-off of Utrecht UMC. By offering a SAAS application for industrial use, under the philosophy of “Internet of Things”, that can be quickly. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact.īigfinite USA Private Bigfinite is global partner in providing simple solutions to the analysis and control complex needs of industrial processes in Biotech and Pharma, covering all the supply chain, from R+D to patient dispensing. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed Co, Ltd China Private InxMed is a clinical-stage biotech company established in the end of 2018. We also have R&D labs at Suzhou and Hong Kong Science & Technology Park (HKSTP) to study the mechanisms of Treg cells and innate immunity in cancer.

Our HQ is located in Zhuhai, China, with R&D capabilities including antibody discovery, process development and analytical assessment platforms, including a pilot plant that would facilitate IND-enabling activities.

OCKHAM RESEARCH COMPANY ARCHIVE

VentureRadar Research / Company WebsiteĪssociated sectors: Biotech Website archive shows the site was first archived on 2013.īiotheus China Private Founded in April 2018, we are a biotech startup focusing on the discovery and development of next generation antibody-based therapeutics. Ockham Biotech Ltd are seeking partners for the commercialisation of inhaled heparin in COPD, bronchiectasis, asthma, cystic fibrosis and other diseases characterised by airway obstruction with mucus. is a research company which is focussed on the development of inhaled heparin for the treatment of obstructive airway diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma.

Ockham research company